Provident Healthcare Partners Advises Acentus in its Acquisition by Henry Schein
Henry Schein (HSIC) has completed the acquisition of substantially all assets of Acentus, a national medical supplier specializing in Continuous Glucose Monitors (CGMs). The deal, initially announced on November 20, 2024, brings Acentus founders Brett Carroll, Todd Cianfrocca, Greg Duvall, and Julio Valdivia into Henry Schein's team, incorporating their healthcare industry and product expertise.
The transaction was facilitated by Provident Healthcare Partners, with their deal team led by Managing Director Kevin Palamara. Robinson & Cole provided legal counsel to Acentus during the acquisition process. Acentus has developed a distinctive CGM platform that has shown significant growth since its establishment.
Henry Schein (HSIC) ha completato l'acquisizione di sostanzialmente tutti gli asset di Acentus, un fornitore medico nazionale specializzato in Monitoraggi Continui della Glucosio (CGM). L'accordo, annunciato inizialmente il 20 novembre 2024, porta i fondatori di Acentus, Brett Carroll, Todd Cianfrocca, Greg Duvall e Julio Valdivia, nel team di Henry Schein, integrando la loro esperienza nel settore sanitario e nei prodotti.
La transazione è stata facilitata da Provident Healthcare Partners, con il loro team di negoziazione guidato dal Direttore Generale Kevin Palamara. Robinson & Cole ha fornito consulenza legale ad Acentus durante il processo di acquisizione. Acentus ha sviluppato una piattaforma CGM distintiva che ha mostrato una crescita significativa sin dalla sua fondazione.
Henry Schein (HSIC) ha completado la adquisición de prácticamente todos los activos de Acentus, un proveedor médico nacional especializado en Monitores Continuos de Glucosa (CGM). El acuerdo, originalmente anunciado el 20 de noviembre de 2024, incorpora a los fundadores de Acentus, Brett Carroll, Todd Cianfrocca, Greg Duvall y Julio Valdivia, al equipo de Henry Schein, integrando su experiencia en la industria de la salud y en productos.
La transacción fue facilitada por Provident Healthcare Partners, con su equipo de negociación liderado por el Director General Kevin Palamara. Robinson & Cole proporcionó asesoría legal a Acentus durante el proceso de adquisición. Acentus ha desarrollado una plataforma CGM distintiva que ha mostrado un crecimiento significativo desde su establecimiento.
헨리 샤인 (HSIC)은 Acentus의 대부분 자산을 인수 완료했습니다. Acentus는 지속 혈당 모니터(CGM)를 전문으로 하는 전국 의료 공급업체입니다. 이 거래는 2024년 11월 20일 처음 발표되었으며, Acentus의 창립자 Brett Carroll, Todd Cianfrocca, Greg Duvall 및 Julio Valdivia를 헨리 샤인의 팀에 통합하여 그들의 의료 분야 및 제품 전문 지식을 포함하고 있습니다.
이 거래는 Provident Healthcare Partners에 의해 원활하게 진행되었으며, 협상 팀은 Kevin Palamara 전무가 이끌었습니다. Robinson & Cole은 인수 과정에서 Acentus에 법률 자문을 제공했습니다. Acentus는 설립 이후 눈에 띄는 성장을 보여준 독특한 CGM 플랫폼을 개발했습니다.
Henry Schein (HSIC) a achevé l'acquisition de presque tous les actifs de Acentus, un fournisseur médical national spécialisé dans les Moniteurs Glycémiques Continus (CGM). L'accord, annoncé initialement le 20 novembre 2024, intègre les fondateurs d'Acentus, Brett Carroll, Todd Cianfrocca, Greg Duvall et Julio Valdivia, dans l'équipe de Henry Schein, incorporant leur expertise dans l'industrie de la santé et les produits.
La transaction a été facilitée par Provident Healthcare Partners, avec leur équipe de négociation dirigée par le Directeur Général Kevin Palamara. Robinson & Cole a fourni des conseils juridiques à Acentus durant le processus d'acquisition. Acentus a développé une plateforme CGM distincte qui a montré une croissance significative depuis sa création.
Henry Schein (HSIC) hat die Übernahme von nahezu allen Vermögenswerten von Acentus, einem nationalen medizinischen Anbieter, der auf kontinuierliche Glukosemonitore (CGMs) spezialisiert ist, abgeschlossen. Die Vereinbarung, die ursprünglich am 20. November 2024 angekündigt wurde, bringt die Gründer von Acentus, Brett Carroll, Todd Cianfrocca, Greg Duvall und Julio Valdivia, ins Team von Henry Schein und integriert deren Fachwissen in der Gesundheitsbranche und zu Produkten.
Die Transaktion wurde von Provident Healthcare Partners erleichtert, deren Verhandlungsteam von Geschäftsführer Kevin Palamara geleitet wurde. Robinson & Cole lieferte während des Übernahmeprozesses rechtlichen Rat an Acentus. Acentus hat eine einzigartige CGM-Plattform entwickelt, die seit ihrer Gründung ein erhebliches Wachstum gezeigt hat.
- Acquisition expands Henry Schein's presence in the growing CGM market
- Integration of Acentus's experienced leadership team strengthens expertise
- Acquisition of established CGM platform with proven growth track record
- None.
Insights
The acquisition of Acentus by Henry Schein (HSIC) represents a strategic expansion into the rapidly growing Continuous Glucose Monitoring (CGM) market. The CGM sector has been experiencing substantial growth, driven by increasing diabetes prevalence and the shift toward continuous monitoring solutions. Integration of Acentus's specialized distribution network and expertise should strengthen Henry Schein's position in the medical supplies segment.
The retention of Acentus's founding team is particularly valuable, bringing domain expertise in CGM distribution and established relationships with manufacturers and healthcare providers. This human capital acquisition could accelerate Henry Schein's penetration into the diabetes care market, estimated to reach
For investors, this bolt-on acquisition aligns with Henry Schein's strategy of expanding its medical business through targeted acquisitions in high-growth segments. While financial terms weren't disclosed, the deal's impact on Henry Schein's
The acquisition enhances Henry Schein's distribution capabilities in the specialized CGM market, which requires unique handling and delivery protocols. Acentus's established infrastructure for CGM distribution provides immediate market access and operational expertise in a complex product category that demands precise logistics and healthcare compliance.
The timing is opportune as the CGM market is experiencing a shift from hospital to home-based monitoring, creating increased demand for efficient distribution networks. Acentus's focused expertise in CGM logistics complements Henry Schein's broader medical distribution platform, potentially creating cross-selling opportunities across their combined customer base.
In simple terms: Think of this like adding a specialized delivery service that knows exactly how to handle and deliver sensitive medical devices to a company that already delivers lots of medical supplies. It's like adding a premium delivery service to an already successful shipping company.
Provident's deal team was led by Managing Director Kevin Palamara. Robinson & Cole served as legal counsel to Acentus. The agreement to acquire Acentus was announced on November 20, 2024.
"Hats off to the entire Provident team. They brought unmatched expertise, experience, and dedication to the process and their guidance and professionalism throughout the transaction exceeded all our expectations," commented Todd Cianfrocca, CEO of Acentus.
"Congratulations to Acentus on this significant achievement. It has been a pleasure working alongside Todd and his entire team throughout this process," commented Palamara.
"Todd and the Acentus team have developed a unique and differentiated CGM platform that has realized tremendous growth since its inception. We were proud to represent them through this process and are incredibly excited to see where this partnership with Henry Schein will take them going forward," stated Brendan Schroeder, Senior Associate at Provident.
About Acentus
Headquartered in
About Henry Schein
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With approximately 26,000 Team Schein Members worldwide, the company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in
About Provident Healthcare Partners
Provident is a leading healthcare investment banking firm specializing in merger and acquisition advisory, strategic planning, and capital formation services for healthcare companies. The firm has a comprehensive knowledge of market sectors and specialties, including the durable medical equipment (DME) industry. Provident also has unsurpassed experience and insight into the M&A process, which includes working with a multitude of investors such as private equity firms and strategic consolidators. For additional information, visit www.providenthp.com and follow Provident on LinkedIn.
Contact: | |
Provident Healthcare Partners | |
877-742-9800 | |
gcasiello@providenthp.com |
View original content to download multimedia:https://www.prnewswire.com/news-releases/provident-healthcare-partners-advises-acentus-in-its-acquisition-by-henry-schein-302352624.html
SOURCE Provident Healthcare Partners LLC
FAQ
When did Henry Schein (HSIC) complete the acquisition of Acentus?
What does Acentus bring to Henry Schein's (HSIC) business portfolio?
Which Acentus executives are joining Henry Schein (HSIC) after the acquisition?
Who advised Acentus in the acquisition by Henry Schein (HSIC)?
